Home  /  Capabilities  /  CI & BD Advisory
Capability 01 · Competitive Intelligence & BD Advisory

Precision Intelligence That Drives Growth Decisions

Bespoke frameworks that turn landscapes, pipelines and deal flow into strategic choices: what to develop, where to compete and whom to partner with.

Service Pillars

Four Pillars, One Integrated View of Your Market

01

Competitive Intelligence

Stay ahead of the competition.

  • Market research & landscape analysis
  • Competitor profiling & benchmarking
  • Early-warning systems for market shifts
  • Conference coverage & tailored intelligence bulletins
02

Commercial Strategy

Optimise your commercial approach.

  • Market segmentation & targeting
  • Go-to-market & launch strategy
  • Brand positioning & pricing strategy
  • Market access & payer strategy
03

Disease & Market Intelligence

Deep insight into disease areas.

  • Epidemiology & market sizing (TAM / SAM / SOM)
  • Treatment landscape analysis
  • Unmet-need identification
  • Therapy-area entry & sequencing
04

Business Development & Partnering

Strategic growth through partnering.

  • Partner identification & evaluation
  • In/out-licensing & deal structuring
  • Asset scouting & scientific / commercial due diligence
  • Portfolio optimisation & management
How We Work

A Four-Step Intelligence Cycle

A continuous loop: each implementation sharpens the next definition, so intelligence stays live rather than shelved.

Define

Objectives, project needs, and direct and indirect competitors.

Gather

Secondary research, KOL and stakeholder interviews, syndicated databases.

Analyse

SWOT, landscape and gap analysis; pressure-test assumptions through the 4W lens.

Implement

Competitive briefs, recommendations, ongoing bulletins and alerts.

Define, Gather, Analyse, Implement intelligence cycle Decision-ready Insight 1DEFINE 2GATHER 3ANALYSE 4IMPLEMENT
Typical Questions We Answer

From Landscape to Licence

  1. How crowded is this mechanism, and where is the white space?
  2. What is the real addressable patient population across our target markets and care settings?
  3. Which partners can take our asset into new territories, and on what terms?
  4. Should we enter now, and with which launch sequence, price and access strategy?
Tablet showing business growth analytics in front of data dashboards
Track Record

Intelligence That Has Shaped Real Decisions

$150M
20-year CAR-T out-licensing deal across South Africa, Morocco and Algeria
$700M
Savings potential from a revised, CI-led clinical development plan for a European pharma major
20+
Person life sciences CI team built and led for a Swiss pharma major

Delivered by the founder in prior senior roles. Client identities withheld.

Have a Landscape, Licensing or Launch Question?

A 30-minute scoping call is usually enough to frame the decision and the approach.

Book a Scoping Call